CanagliflozinEuglycaemic diabetic ketoacidosis during an off-label use: case report

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2020年 / 1787卷 / 1期

关键词：

D O I：

10.1007/s40278-020-73766-9

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：128 / 128

相关论文

共 50 条

[21] Multiple drugsEuglycaemic diabetic ketoacidosis, lack of efficacy and off-label use following exposure during pregnancy: case report
Reactions Weekly, 2022, 1896 (1) : 302 - 302
[22] SarilumabThrombocytopenia during an off-label use: case report
Reactions Weekly, 2020, 1833 (1) : 345 - 345
[23] RiociguatHypotension during off-label use: case report
Reactions Weekly, 2023, 1941 (1) : 321 - 321
[24] IvabradineDizziness during off-label use: case report
Reactions Weekly, 2018, 1691 (1) : 169 - 169
[25] IvabradinePhosphenes during off-label use: case report
Reactions Weekly, 2018, 1688 (1) : 137 - 137
[26] AmikacinNephrotoxicity during off-label use: case report
Reactions Weekly, 2022, 1918 (1) : 36 - 36
[27] CanagliflozinEuglycaemic diabetic ketoacidosis and Fanconi syndrome: case report
Reactions Weekly, 2018, 1704 (1) : 75 - 75
[28] CanagliflozinEuglycaemic ketoacidosis: case report
Reactions Weekly, 2020, 1803 (1) : 69 - 69
[29] Off-label use of topical metronidazole in diabetic ulcer: a case report
Sebastiao, R.
Amad, A.
Salvador, J.
DIABETES RESEARCH AND CLINICAL PRACTICE, 2024, 209
[30] ThiamazoleFebrile neutropenia during off-label use: case report
Reactions Weekly, 2023, 1986 (1) : 413 - 413

← 1 2 3 4 5 →